Represents the amortization of capitalized fees paid to a related party.

No definition available.

Name:	thrx_AmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the age limit for approved use of product.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementAgeLimitForApprovedUse
Namespace Prefix:	thrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate for combination products.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential future contingent payments that the entity is eligible to receive.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementContingentPaymentThatEntityCouldEarn
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the number of combination products which may be launched under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementNumberOfCombinationProductsToBeLaunched
Namespace Prefix:	thrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum amount of potential milestone payments that could be payable.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementObligationForMilestonePayments
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned under collaborative arrangements from upfront payments and contingent payments.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementsRevenue
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents.

+ References

No definition available.

+ Details

Name:	thrx_RoyaltyRevenueFromRelatedPartyNet
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Balance held at close of period in number of shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-12C.Column B)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611225-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14.Column B)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611322-123010

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 1

-Subparagraph (SX 210.12-12.Column B)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611133-123010

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 12C

-Paragraph Column B

-Article 12

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 12

-Paragraph Column B

-Article 12

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 14

-Paragraph Column B

-Article 12

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=thrx_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=thrx_CommonStockUnspecifiedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thrx_LABACollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thrx_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements (Details) (USD $)	3 Months Ended
Collaborative Arrangements (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party	$ (3,456,000)	$ (1,780,000)
Royalty revenue	6,674,000thrx_RoyaltyRevenueFromRelatedPartyNet	(1,050,000)thrx_RoyaltyRevenueFromRelatedPartyNet
Revenue from Collaborative Arrangements	222,000thrx_CollaborativeArrangementsRevenue	270,000thrx_CollaborativeArrangementsRevenue
Total revenue	6,896,000us-gaap_Revenues	(780,000)us-gaap_Revenues
Common stock \| Theravance Biopharma
Information related to collaborative arrangements
Number of ordinary shares owned as marketable securities (in shares)			436,802
GSK
Information related to collaborative arrangements
Royalties from a related party	10,130,000	730,000
Less: amortization of capitalized fees paid to a related party	(3,456,000)	(1,780,000)
Royalty revenue	6,674,000	(1,050,000)
Total revenue	6,896,000	(780,000)
GSK \| MABA
Information related to collaborative arrangements
Potential future contingent payments receivable	363,000,000
Long-acting beta agonist (LABA) collaboration \| GSK
Information related to collaborative arrangements
Number of combination products	2
Obligation for milestone payments			220,000,000
Royalty rate for first level of annual global net sales (as a percent)	15.00%
Annual global sales level used to determine royalty rate	3,000,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)	5.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| Minimum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)	6.50%
Long-acting beta agonist (LABA) collaboration \| GSK \| Maximum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)	10.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| FF/VI \| Minimum
Information related to collaborative arrangements
Age limit for use	18 years
2004 Strategic alliance \| GSK \| MABA
Information related to collaborative arrangements
Revenue from Collaborative Arrangements	$ 222,000	$ 270,000